Suppr超能文献

初发轻度慢性丙型肝炎的自然史

Natural history of initially mild chronic hepatitis C.

作者信息

Alberti A, Benvegnù L, Boccato S, Ferrari A, Sebastiani G

机构信息

Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy.

出版信息

Dig Liver Dis. 2004 Oct;36(10):646-54. doi: 10.1016/j.dld.2004.06.011.

Abstract

The hepatitis C virus is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma in western countries. Chronic hepatitis C is highly heterogeneous and many patients present with a mild form of liver disease. Population-based studies have indeed demonstrated that around 50% of hepatitis C virus carriers have persistently normal ALT and two-third have mild histological liver lesions. Studies on the natural history of initially mild chronic disease indicate that the short-term outcome is always benign. However, progression of liver fibrosis can be observed at long-term (>5-7 years) follow-up, particularly in those cases who have elevated and/or fluctuating transaminase levels. Observational prospective studies and outcome modelling projections indicate that the risk of liver disease progression towards severe fibrosis/cirrhosis is minimal at 10-15 years in hepatitis C virus carriers with persistently normal ALT, around 5-10% in patients with elevated ALT and F0 (no fibrosis) in the initial biopsy but >30-40% in chronic carriers with elevated ALT and F1 (portal fibrosis) in the initial biopsy. Cofactors like age at infection, alcohol, coinfections and liver steatosis accelerate disease progression. On the basis of these findings, patients with initially mild chronic hepatitis C and elevated ALT should be proposed for antiviral therapy in the absence of contraindications.

摘要

在西方国家,丙型肝炎病毒是导致慢性肝病、肝硬化和肝细胞癌的主要原因。慢性丙型肝炎具有高度异质性,许多患者表现为轻度肝病。基于人群的研究确实表明,约50%的丙型肝炎病毒携带者谷丙转氨酶(ALT)持续正常,三分之二有轻度肝脏组织学病变。对最初为轻度慢性疾病自然史的研究表明,短期预后总是良性的。然而,在长期(>5 - 7年)随访中可观察到肝纤维化进展,特别是在转氨酶水平升高和/或波动的患者中。观察性前瞻性研究和预后模型预测表明,ALT持续正常的丙型肝炎病毒携带者在10 - 15年发展为严重纤维化/肝硬化的肝病进展风险极小,初始活检ALT升高且F0(无纤维化)的患者中约为5 - 10%,而初始活检ALT升高且F1(门脉纤维化)的慢性携带者中则>30 - 40%。感染时的年龄、酒精、合并感染和肝脂肪变性等协同因素会加速疾病进展。基于这些发现,对于最初为轻度慢性丙型肝炎且ALT升高的患者,在无禁忌证的情况下应建议进行抗病毒治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验